OPRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
OPRX is not a good buy right now for an impatient investor. Despite being technically oversold and showing bullish options positioning, the prevailing trend is still bearish (downward momentum + bearish moving-average stack), and there is no Intellectia proprietary buy signal to justify stepping in immediately. A tradable bounce is possible near support, but the higher-probability setup for an immediate buy would require confirmation (stabilization above ~11.71 pivot and improving momentum).
Price/Trend: Bearish trend structure with SMA_200 > SMA_20 > SMA_5, indicating the stock is trading in a defined downtrend across short-to-long timeframes. Momentum: MACD histogram is -0.105 and negatively expanding, suggesting downside momentum is still strengthening rather than bottoming. Oscillators: RSI_6 at 21.767 indicates the stock is oversold (even if labeled “neutral” in the feed, 21 is classically oversold), which can fuel short-term rebounds—but oversold can persist in a downtrend. Levels: Immediate support is S1=10.721 (pre-market ~10.83 is sitting just above it). If this breaks, next support is S2=10.108. Upside recovery would first need to reclaim Pivot=11.714, then R1=12.708. Pattern/Probabilities: Similar-pattern projection shows a modest next-day bias (-0.6%) but positive skew over 1 week (+7.97%) and 1 month (+5.41%), consistent with “oversold bounce” potential rather than confirmed trend reversal.
Intellectia Proprietary Trading Signals
Oversold setup near support (S1 ~10.
can enable a snapback rally if selling pressure exhausts.
Options market skew is notably call-heavy (bullish near-term sentiment).
Analyst community is broadly constructive post-Q3, with multiple Buy/Outperform ratings and higher targets following the strong quarter and improved visibility.
Q3 revenue growth remained strong (+22.33% YoY) and gross margin improved (+8.76% YoY), supporting the “operational momentum” narrative.
The dominant trend is still bearish (SMA stack bearish; MACD negative and worsening), increasing the odds any bounce is sold.
Profitability deteriorated sharply in the latest quarter (Net Income and EPS down ~108% YoY), which can cap upside until earnings quality improves.
No fresh news/catalysts in the last week to force a re-rating or reverse momentum immediately.
One notable dissent: Stephens kept Equal Weight and cut target to $17 (from $20), explicitly calling risk/reward “balanced” after a large run-up.
Latest quarter: 2025/Q3. Growth: Revenue rose to $26.067M (+22.33% YoY), indicating demand and topline execution improved. Margins: Gross margin increased to 63.05% (+8.76% YoY), a positive quality signal. Profitability: Net income fell to $0.779M (-108.54% YoY) and EPS to $0.04 (-108.00% YoY), showing earnings power weakened materially versus last year despite better margins—suggesting higher operating costs, investments, or other below-the-line pressure. Overall: strong revenue/margin trend, weak bottom-line trend.
Recent trend: On 2025-11-07, multiple firms raised price targets and reiterated Buy/Outperform (B. Riley $28, Lake Street $24, Roth $32, Stifel $21, Citizens JMP $24) following a strong Q3 and improved forward visibility/guidance. On 2025-11-17, Stephens trimmed its target to $17 and maintained Equal Weight, citing a more balanced risk/reward after the stock’s big move. Wall Street pros: improving momentum, multiple strong quarters, better visibility, expectation of double-digit growth and potential margin expansion. Wall Street cons: after a large run-up, risk/reward may be less asymmetric; profitability volatility (recent net income/EPS drop) introduces execution risk. Influential/political trading: No recent congress trading data available; hedge funds and insiders show neutral activity in the provided dataset.
